ArticleMethodsX2026
Efficacy of the digital health application ORIKO
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) often continues into adulthood and affects several million adults in Germany. Many do not receive timely, evidence-based treatment because of long waiting times and limited access to care. Digital health applications offer a low-threshold option to provide guideline-based support. A pilot study of the present app-based program showed encouraging improvements in quality of life and reductions in ADHD symptom severity. This randomized controlled trial (RCT) aims to confirm and extend the pilot findings. The primary objective is to examine whether the digital intervention improves quality of life in adults with ADHD. Further outcomes include changes in ADHD symptoms, functional impairment, depressive and anxiety symptoms, substance use, general health, health literacy, medication adherence, and user satisfaction. A total of 380 adults with verified ADHD will be recruited online and via a university hospital. After informed consent and baseline assessment, participants will be randomized 1:1 to immediate access to a 12-week digital unguided program or to care as usual (CAU). Self-report assessments will take place at baseline, 6 weeks, and 12 weeks. Mixed models for repeated measures will be used for the primary analyses, complemented by intention-to-treat and complete-case approaches. The trial will test the robustness of the previous pilot results and provide evidence on the clinical value of a scalable digital intervention for adult ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.